1. Home
  2. QNRX vs MBAI Comparison

QNRX vs MBAI Comparison

Compare QNRX & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

HOLD

Current Price

$7.45

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.57

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
QNRX
MBAI
Founded
2018
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
10.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
QNRX
MBAI
Price
$7.45
$1.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.7K
7.2M
Earning Date
03-12-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.01
$0.59
52 Week High
$41.80
$3.92

Technical Indicators

Market Signals
Indicator
QNRX
MBAI
Relative Strength Index (RSI) 33.58 45.20
Support Level $7.07 $1.31
Resistance Level $8.46 $1.58
Average True Range (ATR) 0.88 0.44
MACD -0.13 -0.05
Stochastic Oscillator 19.75 8.24

Price Performance

Historical Comparison
QNRX
MBAI

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: